PCO371

Non Chimik:

1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl))-1,3,8-triazaspiro[4.5]dec-1-en-8-yl )sulfonyl)etil)fenil)-5,5-dimethylimidazolidine-2,4-dyon

Kòd SMILES:

O=C1NC(C(C)(C)N1C2=CC(C)=C(CCS(=O)(N(CC3)CCC3(N=C(C4=CC=C(OC(F)(F))F)) )C=C4)N5)C5=O)=O)C(C)=C2)=O

Kòd InChi:

InChI=1S/C29H32F3N5O6S/c1-17-15-20(37-26(40)34-24(38)27(37,3)4)16-18(2)22(17)9-14-44( 41,42)36-12-10-28(11 -13-36)25(39)33-23(35-28)19-5-7-21(8-6-19)43-29(30,31)32/h5-8,15-16H,9 -14H2,1-4H3,(H,33,35,39)(H,34,38,40)

InChi kle:

LDZJFVOUPUFOHX-UHFFFAOYSA-N

Mot:

PCO371; PCO-371; PCO 371

Solibilite: 

Depo: 

Deskripsyon:

PCO371 se yon agonist PTHR1 ki pisan ak selektif pou tretman ipoparathyroidism. Administrasyon oral PCO371 nan rat osteopenik pwovoke yon ogmantasyon siyifikatif nan woulman zo ak ogmantasyon limite nan mas zo. Nan rat hypocalcemic, PCO371 retabli nivo kalsyòm serik san yo pa ogmante kalsyòm urin, ak efè pi fò ak ki dire lontan pase piki PTH.

Sib: PTHR1